We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




RYGB Patients Face Higher Risk of Additional Operations

By HospiMedica International staff writers
Posted on 02 Jan 2020
A new study suggests that patients undergoing vertical sleeve gastrectomy (VSG) have a lower risk of subsequent operative intervention than those undergoing Roux-en-Y gastric bypass (RYGB).

Researchers at Harvard Medical School (HMS; Boston, MA, USA), Wake Forest School of Medicine (Winston-Salem, NC, USA), and other institutions used data from a U.S. More...
national insurance claims database of adults who underwent a first RYGB or VSG procedure between January 1, 2010, and June 30, 2017. The final weighted matched sample included 4,476 patients undergoing RYGB and 8,551 patients undergoing VSG, with the primary outcome being any abdominal operative intervention after the index procedure. Secondary outcomes included biliary procedures, abdominal wall hernia repair, bariatric conversion or revision, other abdominal operations, and endoscopy and enteral access.

The results revealed that in patients followed up for up to four years after surgery, those undergoing VSG were less likely to have any subsequent operative intervention than matched patients undergoing RYGB. They were similarly less likely to undergo biliary procedures, abdominal wall hernia repair, other abdominal operations, and endoscopy or enteral access placed. The patients undergoing VSG were also more likely to undergo bariatric conversion or revision. The study was published on December 18, 2019, in JAMA Network Open.

“Patients undergoing VSG appeared to be less likely than matched patients undergoing RYGB to experience subsequent abdominal operative interventions, except for bariatric conversion or revision procedures,” concluded senior author James Wharam, BCh, MPH, of HMS, and colleagues. “Patients considering bariatric surgery should be aware of the increased risk of subsequent procedures associated with RYGB. It's important for patients to understand not only the many benefits of bariatric surgery, but also the risks, including the possible need for more surgery down the road.”

VSG is a restrictive form of weight loss surgery intended for the morbidly obese which reduces the size of the stomach by removing the lateral 2/3 of the stomach with a stapling device. While the stomach is drastically reduced in size, function is preserved, with no malabsorption of nutrients and supplements. The procedure avoids problems associated with bypass forms of weight loss surgery, including anemia, intestinal obstruction or blockage, osteoporosis, and protein and vitamin deficiency, and since about 100-200 ml of stomach capacity is maintained, there are very few restrictions on food consumption.

Related Links:
Harvard Medical School
Wake Forest School of Medicine



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.